The oncogenic gene ZNF703 was proven to be the target binding miR-185-5p.

LSINCT5 is abnormally upregulated in OSCC specimens and drives its malignant progression through the miR-185-5p/ZNF703 axis.

LSINCT5 is abnormally upregulated in OSCC specimens and drives its malignant progression through the miR-185-5p/ZNF703 axis.

To investigate the efficacy and safety of nimotuzumab + cisplatin and 5-fluorouracil (PF) induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.

The clinical data of 126 patients with stage III-IVa nasopharyngeal carcinoma who were admitted to and treated in our department from September 2013 to May 2016 were collected, and the patients were randomly divided into two groups and treated with nimotuzumab combined with PF induction therapy (NPF group, n=65) and induction therapy of docetaxel, cisplatin and fluorouracil (TPF) regimen (TPF group, n=65). After 2 cycles of induction therapy, all the patients received cisplatin combined with concurrent intensity-modulated radiation therapy (IMRT). Moreover, the clinical efficacy, changes in patients’ quality of life and incidence of adverse reactions were observed and compared between the two groups, and the survival of the patients was followed up and recorded.

The objective response rate (ORR) cacy in treating locally advanced nasopharyngeal carcinoma, higher quality of life and long-term survival rate as well as tolerable adverse reactions.

Cell-free DNA (cfDNA) in plasma is a useful resource for liquid biopsy. The concentration and integrity of cfDNA may be clinical informative for detecting and predicting cancer progression.

Plasma from 40 healthy controls and 90 colorectal cancer patients was assessed. Acetohydroxamic mw qPCR targeting the arithmetic-logic unit (Alu) repeats were performed using two different sets of primers amplifying the long and short segments. DNA integrity was calculated by the ratio of the long to the short fragments of amplified Alu repeats.

cfDNA concentration was significantly higher in the patients than that in healthy controls. Patients with stage III colorectal cancer showed no significant difference in their cfDNA levels as compared with the healthy controls. In colorectal cancer, cfDNA level of stage IV patients was higher than that of stage 0-III (p=0.049). The DNA integrity was significantly lower in patients with stage I and II cancer than that in normal controls (p=0.007, 0.029 respectively). The receiver operating characteristic (ROC) curve for discriminating patients with colorectal cancer from normal controls had an area under the curve of 0.672 (95%CI, 0.572 to 0.772) and cfDNA concentration increased within 21 days following surgery and dropped by 3 months after surgery.

Concentration of cfDNA is a promising molecular marker for assessing colorectal cancer progression. Both the cfDNA concentration and its integrity are highly variable. Some cancer stage dependent changes were observed, which warrants further investigation with more patients included.

Concentration of cfDNA is a promising molecular marker for assessing colorectal cancer progression. Both the cfDNA concentration and its integrity are highly variable. Some cancer stage dependent changes were observed, which warrants further investigation with more patients included.

To explore the efficacy and safety of cetuximab plus chemotherapy in the treatment of metastatic colorectal cancer (mCRC), and to analyze the possible factors affecting the prognosis.

Clinical data were collected from 136 patients who were definitely diagnosed with mCRC in our hospital from January 2015 to December 2016, and whose genetic test showed wild-type (WT) Kirsten Ras (KRAS), and they were randomly divided into two groups and underwent cetuximab plus chemotherapy (n=68, Cetuximab group) or only chemotherapy (n=68, Chemotherapy group). The clinical short-term efficacy, incidence of adverse reactions and quality-of-life score of patients were compared between the two groups, and the survival and disease progression were recorded during follow-up.

After treatment, there were statistically significant differences between Cetuximab group and Chemotherapy group regarding objective response rate (ORR) and disease control rate (DCR) [69.1% (47/68) vs. 60.3% (41/68), 85.3% (58/68) vs. 79.4% (54/68)] (p=41].

Cetuximab plus chemotherapy has exact efficacy in treating mCRC, and it results in a higher long-term survival rate and a lower disease progression rate than chemotherapy alone, improves the quality of life of patients and produces tolerable adverse reactions. Besides, poor tumor differentiation is an independent risk factor for the mPFS and mOS of patients.

Cetuximab plus chemotherapy has exact efficacy in treating mCRC, and it results in a higher long-term survival rate and a lower disease progression rate than chemotherapy alone, improves the quality of life of patients and produces tolerable adverse reactions. Besides, poor tumor differentiation is an independent risk factor for the mPFS and mOS of patients.

To explore the efficacy and safety of apatinib mesylate in the third-line treatment of advanced colorectal cancer after the standard second-line treatment failed, and to analyze the possible factors affecting the prognosis.

The clinical data of 52 patients with advanced colorectal cancer who failed or were intolerant of the standard second-line treatment performed in our hospital from January 2017 to December 2018 were collected. All the patients received the third-line treatment with apatinib mesylate tablets that were administered at 500 mg q.d. with 28 d as an administration cycle, and the clinical efficacy of apatinib mesylate and incidence of adverse reactions were recorded and analyzed. Besides, the survival and disease progression of the patients were followed up and recorded, and the influencing factors for the prognosis were analyzed.

The remaining 50 patients had efficacy evaluation, and it was found that the overall response rate (ORR) and disease control rate (DCR) were 8.0% (4/50) and 50% ( after treatment, which are the independent factors affecting the efficacy.

Apatinib is effective in the third-line treatment of advanced colorectal cancer, significantly improves the patient quality of life, and causes tolerable adverse reactions. The mPFS is markedly extended in the patients with CerB2++/+++, positivity rate of Ki-67 ≥50% and the presence of hypertension after treatment, which are the independent factors affecting the efficacy.